Clinical Takeaway
People with PTSD and co-occurring substance use disorders who use cannabis can still benefit meaningfully from trauma-focused treatments. Cannabis use does not appear to prevent or significantly undermine the effectiveness of evidence-based PTSD therapies in this population.
#6 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis addresses a critical clinical gap by examining whether evidence-based trauma-focused treatments maintain efficacy in the substantial subset of PTSD+SUD patients who use cannabis, a population often excluded from traditional efficacy trials. The findings directly inform treatment selection and sequencing decisions for dually diagnosed patients, who represent a significant proportion of clinical caseloads but lack adequate guidance on optimal intervention strategies. Understanding treatment response patterns in cannabis users with co-occurring PTSD and SUD enables clinicians to make data-driven decisions about whether to initiate trauma-focused therapy, modify dosing, or address substance use concurrently.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis contributes valuable data on an underexplored population, several important limitations warrant cautious interpretation in clinical practice. The analysis draws from only four RCTs nested within a larger project, which substantially constrains generalizability and statistical power to detect meaningful differences between cannabis users and non-users with co-occurring PTSD and SUD. The heterogeneity of cannabis use patterns, concurrent polysubstance involvement, and variations in trauma-focused treatment protocols across the included trials create confounding that is difficult to fully disentangle, and the analysis does not clarify whether cannabis use reflects self-medication, contributes to treatment dropout, or truly impairs therapeutic outcomes. Given the real-world prevalence of cannabis use in this vulnerable population and the relative scarcity of evidence-based treatment options, a null or modest finding would not necessarily justify withholding trauma-focused care from cannabis users, but rather should encourage shared decision-making about concurrent use and potentially more intensive monitoring during treatment. In practice, trauma-